1) The document discusses prevention and treatment strategies for oral squamous cell carcinoma (OSCC), a common type of oral cancer. 2) It describes a proposed phase IIB clinical trial called EPOC that would test the drug Erlotinib for preventing oral cancer in high-risk patients. 3) A second proposed clinical trial would test the drug Pioglitazone for treating oral pre-malignant lesions and examining effects on histology, biomarkers, and cancer risk.